Background: Several autoimmune diseases may occur in the same patient. Celiac disease (CD) is found in patients with diabetes mellitus type-1 and thyroiditis. Few studies have addressed the association between CD and rheumatic disorders such as rheumatoid arthritis (RA).
Objective: To study the prevalence of anti-endomysial antibodies in RA patients.
Methods: The presence of IgA anti-endomysial antibodies (EmA-IgA) was evaluated in 85 RA patients and 97 healthy controls through indirect immunoflourescence using human umbilical cord as substrate.
Results: None of the RA patients or healthy controls was positive for EmA-IgA.
Conclusion: We could not find an association between RA and anti-endomysial antibodies in the studied population.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background: Celiac disease (CD) is an autoimmune disorder in which genetically susceptible individuals cannot digest gluten (wheat) and its homologs such as Scalin (rye) and Hordein (barley).
Aim: This systematic review and meta-analysis aimed to investigate the measures of associations between CD and psychiatric disorders, specifically anxiety and depression, and explore the relationship between adherence to a Gluten-Free Diet (GFD) and the psychiatric aspects of the disease.
Methods: We searched PubMed, Scopus and Web of Science for articles investigating anxiety and depression in CD patients.
Children with celiac disease, diagnosed with or without biopsy, present similar adherence to gluten-free diet and serology decline.
Eur J Pediatr
November 2024
Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
Unlabelled: Current professional guidelines enable diagnosing pediatric Celiac Disease (CeD) without a biopsy, when tissue transglutaminase (TTG) IgA antibodies are > × 10 the upper limit of normal (ULN) and anti-endomysial antibodies (EMA) are positive in a second sample. We compared baseline characteristics and serology normalization in children diagnosed with or without biopsies. A retrospective study of pediatric patients diagnosed with CeD during 2020: group A, no biopsy and group B, biopsy-based diagnosis.
View Article and Find Full Text PDFFinding of celiac disease during the study of Kimura disease in a Caucasian male.
Rev Esp Enferm Dig
November 2024
Medical Oncology, Hospital Universitario de Salamanca.
We present the case of a 27-year-old man, with no previous diseases, who was referred to the Department of Otorhinolaryngology in May 2023 for a 2-cm right submandibular lymphadenopathy of two month's evolution. He did not report fever or night sweats, and no oral or genital ulcers were observed. He presented eosinophilia in the analysis performed and a maculopapular exanthema on the left leg and malleolus areas, which was initially treated with topical antibiotic and corticosteroids.
View Article and Find Full Text PDFCeliac disease autoimmunity among Nigerian children and adolescents with type 1 diabetes mellitus.
BMC Gastroenterol
November 2024
Department of Paediatrics, College of Medicine, University of Lagos, Akoka, Lagos, Nigeria.
Background: Celiac disease (CD) affects the small intestine and can hinder nutrient absorption. It is found worldwide and common in certain groups of people including individuals with Type 1 Diabetes Mellitus (T1DM). However, the prevalence of CD in the West African region is not documented.
View Article and Find Full Text PDFEndomysial antibodies or anti-tissue transglutaminase type 2 IgA antibodies as a confirmatory test in children with celiac disease.
J Pediatr Gastroenterol Nutr
October 2024
Tel-Aviv Sourasky Medical Center, Dana-Dwek Children's Hospital, Pediatric Gastroenterology Institute, Tel Aviv, Israel.
The no-biopsy approach to diagnose celiac disease (CD), introduced in the 2012 European Society for Gastroenterology and Hepatology and Nutrition guidelines, requires an anti-endomysial antibody (EMA) confirmatory serology test following a high-positive immunoglobulin A anti-tissue transglutaminase-2 (anti-TG2) antibody ≥10 times the upper limit of normal (ULN). The aim of this retrospective study is to compare EMA positivity and high-positive anti-TG2 in patients who had their confirmatory test within two month of their first high-positive anti-TG2 test. Among 933 patients who had high-positive anti-TG2 serology more than 10 times the ULN in their first sample, all had both high-positive anti-TG2 and positive EMA, most of them with very high EMA titers (99.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!